ALNY Stock Price Today (September 2026) — Alnylam Pharmaceuticals, Inc. Analysis & Key Metrics 2026-09-03
Alnylam Pharmaceuticals, Inc. (ALNY) is trading at $264.50, down 1.08% today (as of September 2026). The stock continues to show early recovery signs above the short-term average, attracting attention from investors looking for Healthcare growth opportunities.
- According to consensus analyst estimates, the 1-year price target is $370.20 (40.0% upside).
- Volatility remains elevated (45.08% annualized), implying wide price swings for short-term traders.
- The fundamental picture, based on the latest financial filings, is nuanced: solid revenue growth (66.90% YoY) alongside significant competitive pressures.
ALNY Stock Analysis: Key Metrics & Valuation (September 2026)
Concise, actionable data for investors
Alnylam Pharmaceuticals, Inc. - Historical Price & Volume
Market Cap
Enterprise Value: $31.89B
P/E Ratio
Forward P/E: 19.12
Revenue Growth
Year over Year
Analyst Target
+40.0% upside potential
Key Investor Questions About ALNY
What investors need to know before buying
Based on current market data, ALNY presents a neutral technical setup with caution warranted fundamentals.
- Technicals say: Neutral (RSI 68.63)
- Fundamentals say: Caution warranted (high leverage concerns)
ALNY's growth trajectory depends on its ability to expand within the Biotechnology sector while managing margin pressures.
- Future growth will depend on performance in core Biotechnology operations.
- The ability to manage competitive pressures will be crucial for sustained growth.
The primary risks for ALNY investors include debt exposure and competitive dynamics in the Biotechnology industry.
- $2.99B in debt could be a headwind in a high-rate environment.
- Fierce competition from established players in Biotechnology.
52-Week Trading Range
Over the past year, ALNY stock traded between $197.81 and $495.55—recovering meaningfully from lows and currently near the higher end. Big swings are likely unless a major catalyst emerges.
Volatility & Risk Profile
With 45.08% annualized volatility and β=0.73, the stock exhibits low sensitivity to market moves—making ALNY suitable for investors comfortable with active risk management.
Institutional & Insider Ownership
High institutional backing, but elevated short interest signals a potential battleground stock.
Analyst Sentiment & Price Targets
Latest News & Headlines
Recent headlines and coverage
TG Therapeutics (TGTX) Up 15.1% Since Last Earnings Report: Can It Continue?
TG Therapeutics (TGTX) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
4 Rare Disease Drugmakers With Strong Long-Term Growth Prospects
ALNY, BMRN, RARE and BBIO offer rare-disease growth potential through strong products, pipeline catalysts and high unmet medical needs.
Alnylam's Latest Data Strengthen Outlook for Nucresiran, TRITON-CM, Oppenheimer Says
Alnylam Pharmaceuticals' (ALNY) latest data strengthen the case for Nucresiran and TRITON-CM success
Inceptive CEO Jakob Uszkoreit on Designing Medicines That Work Like Life Itself
Inceptive CEO Jakob Uszkoreit goes Inside the ICE House to challenge the foundational assumptions of modern drug discovery, arguing that AI will enable medicines that work with the body's natural complexity rather than against it. He discusses Inceptive's partnership with Alnylam Pharmaceuticals and why their RNA interference platform and rich data history make them a uniquely powerful AI collaborator. Uszkoreit explains why partnerships are essential for a small company with broadly applicable technology, and why the long-term prize is therapies that are gentler, earlier, and truly personalized.
IONS, AZN Stocks Fall On Full Data From Failed Cardiomyopathy Trial — Jefferies Sees Neutral To Negative Readthrough To ALNY
Ionis and AstraZeneca already disclosed on July 9 that the late-stage CARDIO-TTRansform missed its primary goal. Full data from the trial was unveiled on Friday.
Alnylam stock drops on rival heart trial: Why analysts see core business safe
Investing.com -- A major clinical trial failure in heart disease is reverberating across Wall Street, wiping hundreds of millions of dollars off the market value of RNA-therapeutics pioneer Alnylam Pharmaceuticals before the opening bell on Friday. Shares of Alnylam (NASDAQ: ALNY) fell nearly 4.9% in pre-market trading following the full presentation of data from a rival drug trial at the European Society of Cardiology Congress in Munich. The detailed results from AstraZeneca and Ionis Pharmaceu
AstraZeneca, Ionis data spark debate about RNA drugs’ impact on deadly heart disease
Results published in NEJM raised questions about the benefits “silencer” medications provide on top of standard therapies for TTR cardiomyopathy and amplified investor pressure on Alnylam.
Moderna Stock Carries A Market Value Its Revenue Does Not Support
Moderna's commercial business has shrunk and is lossmaking, which puts the weight of its market value on a pipeline rather than on revenue.
Alnylam Pharmaceuticals (ALNY) Stock Looks Cheap After A 47% Fall Yet Rich On Earnings
Alnylam Pharmaceuticals stock has fallen 46.8% over the past year, yet the valuation checks still flag it as leaning expensive rather than a clear bargain. With fresh clinical data on its RNAi programs coming at the ESC Congress 2026, investors are weighing that share price slump against what the current market valuation implies. The share price decline of 46.8% over the last 12 months signals that expectations have come down sharply and raises the question of whether sentiment has weakened...
Alnylam Pharmaceuticals (ALNY) Heads To ESC With New Data, Is It A Bargain?
Alnylam Pharmaceuticals (ALNY) has drawn market attention after announcing plans to present new clinical and real-world data on its ATTR and hypertension RNAi programs at the ESC Congress 2026 in Munich. See our latest analysis for Alnylam Pharmaceuticals. Despite the ESC Congress announcement, Alnylam Pharmaceuticals’ share price has been under pressure, with the stock down 41% year to date and the 1 year total shareholder return declining 47%, although the 3 year total shareholder return...
Explore More Analysis for ALNY
Additional research, tools, and technical breakdowns
Stock Analyzer Report
Deep-dive automated research and stock rating report.
DCF Fair Value Calculator
Discounted cash flow model and intrinsic value projection.
AI Price Predictions
Multi-scenario price predictions and consensus targets.
Insider Activity Tracker
Track buying/selling behavior of corporate insiders.
Earnings Calendar
Track upcoming and historical corporate earnings reports.
Market Insights & Research
Read the latest analysis articles and expert research.
Frequently Asked Questions
Common investor questions about Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals, Inc. (ALNY) is currently trading at $264.50. The RSI (14-day) is at 68.6, indicating neutral territory. Wall Street analysts have a consensus "buy" recommendation. The mean analyst price target of $370.20 implies 40.0% upside from current levels. Volatility is high at 45.1% annualized, meaning significant price swings are common. Investors should consider their risk tolerance, investment horizon, and portfolio diversification before making a decision.
Based on current valuation metrics for Alnylam Pharmaceuticals, Inc. (ALNY): The trailing P/E ratio is 45.45, which is above the market average, indicating investors are pricing in higher growth expectations. The forward P/E is 19.12, lower than the trailing P/E, suggesting analysts expect earnings improvement. The PEG ratio is 0.45, below 1.0, which generally indicates the stock is undervalued relative to its growth rate. Price-to-Book is 26.12. Price-to-Sales is 7.37. Valuation should be compared to Biotechnology industry peers for context, as different sectors trade at different multiples.
Based on 26 analysts covering ALNY, the consensus price target is $370.20. This represents a 40.0% upside from the current price of $264.50. The range spans from a low target of $230.00 to a high target of $536.00, reflecting varying levels of optimism among analysts. The consensus recommendation is "buy". Note: Analyst price targets are forward-looking estimates and not guarantees of future performance.
Alnylam Pharmaceuticals, Inc. (ALNY) does not currently pay a regular dividend. The company may be reinvesting profits into growth initiatives, or may not yet be profitable enough to distribute earnings to shareholders.
Key risks for Alnylam Pharmaceuticals, Inc. (ALNY) investors include: 1. High volatility (45.1% annualized)—the stock can experience significant daily price swings. 2. Elevated debt levels (D/E ratio of 220.62) which could pressure margins in a rising rate environment. 3. Broader market and macroeconomic risks (interest rates, inflation, geopolitical events). 4. Biotechnology sector-specific competitive pressures. Investors should diversify and consider their risk tolerance before investing.
Here is Alnylam Pharmaceuticals, Inc.'s (ALNY) current debt and financial health profile: Total debt stands at $2.99B. The debt-to-equity ratio is 220.62, which is high and could pose financial risk if earnings decline or borrowing costs increase. The current ratio is 3.06, indicating strong short-term liquidity. The quick ratio is 2.79. The company holds $3.31B in cash and equivalents. Free cash flow is positive at $271.54M, providing a cushion for debt servicing and shareholder returns.